Research from Water Tower Research, Water Tower Research

Water Tower Research

Research from Water Tower Research

Water Tower Research is a leading equity research firm that provides research on micro, small and mid cap companies.

Water Tower Research was founded by Wall Street veterans after witnessing a fundamental shift in the investment research industry with the result being a declining knowledge base among investors, a lack of awareness and a shrinking pool of fundamental research being conducted on companies across the small-cap and micro-cap spectrum. The same issues are now increasingly occurring in the mid-cap space. This sea change within the investment community is impacting not only the companies themselves but also current shareholders and potential investors. With significantly less active sell-side sponsorship by Wall Street, a substantial information gap has developed between companies and various constituents in the financial community. The net result is fewer channels for insight and information to flow between companies and investors.

Equity Research Firm

Equity Bottom-Up

<ul><li>Clinical site IRB approval for Veldona Sjogren’s trial. Ainos received Institutional Review Board (IRB) approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the Veldona clinical study in primary Sjogren’s syndrome.</li><li>TFDA approval is expected next quarter, with the site initiation visit to start around April 2025.</li><li>Ainos expects study completion in December 2026.</li></ul>

Clinical site IRB approval for Veldona Sjogren’s trial. Ainos received Institutional Review Board (IRB) approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the Veldona clinical study in primary Sjogren’s syndrome.TFDA approval is expected next quarter, with the site initiation visit to start around April 2025.Ainos expects study completion in December 2026.

Ainos, Inc.: IRB Approval for Veldona Sjogren's Trial

<ul><li>Jack Lu, Director of Corporate Development, joined us on the WTR Small-Cap Spotlight podcast to discuss Veldona, Ainos’ clinical stage low-dose interferon-α (IFN-α)  therapeutic.</li><li>We covered Veldona’s clinical history, therapeutic effects, disease priorities, market opportunity, and timelines for clinical studies.</li><li>Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website.</li></ul>

Jack Lu, Director of Corporate Development, joined us on the WTR Small-Cap Spotlight podcast to discuss Veldona, Ainos’ clinical stage low-dose interferon-α (IFN-α)  therapeutic.We covered Veldona’s clinical history, therapeutic effects, disease priorities, market opportunity, and timelines for clinical studies.Those interested can listen to this podcast on Apple Podcasts, Spotify, or on our website.

Ainos, Inc: WTR Small-Cap Spotlight Recap - Veldona Drug Platform and Clinical Studies

<ul><li>Taiwan Veldona human study to start in Sjogren’s.</li><li>Ainos will initiate a Veldona clinical study in Taiwan for primary Sjogren’s syndrome in December 2024.</li><li>This follows the announcement of an oral warts in HIV+ clinical study planned for November 2024. </li></ul>

Taiwan Veldona human study to start in Sjogren’s.Ainos will initiate a Veldona clinical study in Taiwan for primary Sjogren’s syndrome in December 2024.This follows the announcement of an oral warts in HIV+ clinical study planned for November 2024. 

Ainos, Inc. - Veldona Sjogren's Study Start to Quickly Follow Oral Warts

<ul><li>Veldona study design under review by TFDA. Ainos plans to initiate a Veldona clinical study in Taiwan for oral warts in HIV+ patients on antiretroviral therapy (ART), with trial start and first patient visit expected in November 2024.</li><li>The single-site, double-blind study will enroll 40 subjects, randomized 3:1 to Veldona or placebo.</li><li>The primary endpoint is the proportion of patients achieving &gt;75% reduction in oral warts surface area at 24 weeks, with secondary endpoints of &gt;50% reduction and patient- and physician-assessed quality of oral health. </li></ul>

Veldona study design under review by TFDA. Ainos plans to initiate a Veldona clinical study in Taiwan for oral warts in HIV+ patients on antiretroviral therapy (ART), with trial start and first patient visit expected in November 2024.The single-site, double-blind study will enroll 40 subjects, randomized 3:1 to Veldona or placebo.The primary endpoint is the proportion of patients achieving &gt;75% reduction in oral warts surface area at 24 weeks, with secondary endpoints of &gt;50% reduction and patient- and physician-assessed quality of oral health. 

Ainos, Inc. -  Veldona Oral Warts Trial to Start in Taiwan Before Year-End

<ul><li>Veldona patent granted in Taiwan for treatment and prevention of coronavirus infection, securing 20 years of patent protection.</li><li>The invention patent covers the method and composition of a Veldona-based therapeutic approach to stimulate the immune system by dosing Veldona through sublingual and/or buccal administration to reduce the risk of symptomatic coronavirus infections.</li><li>Sublingual and/or buccal administration allows Veldona to be rapidly absorbed by the oral mucosa, enabling more effective treatment and better drug compliance. </li></ul>

Veldona patent granted in Taiwan for treatment and prevention of coronavirus infection, securing 20 years of patent protection.The invention patent covers the method and composition of a Veldona-based therapeutic approach to stimulate the immune system by dosing Veldona through sublingual and/or buccal administration to reduce the risk of symptomatic coronavirus infections.Sublingual and/or buccal administration allows Veldona to be rapidly absorbed by the oral mucosa, enabling more effective treatment and better drug compliance. 

Ainos, Inc. - Adding Coronavirus Treatment and Prevention to Veldona Patent Portfolio

United States

Ainos, Inc. is a diversified healthcare company. The Company engages in the discovery and development of novel biopharmaceuticals, technologically medical treatments, and consumer products, as well as provides treatments of neoplastic, viral, and autoimmune diseases. Ainos operates in the United States and Taiwan.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ainos (AIMD US)

Ainos, Inc.: IRB Approval for Veldona Sjogren's Trial

Ainos received Institutional Review Board (IRB) approval from the Shuang Ho Hospital (Taipei Medical University) to conduct the Veldona clinical...

Water Tower Research

Ainos, Inc: WTR Small-Cap Spotlight Recap - Veldona Drug Platform and Clinical Studies

Jack Lu, Director of Corporate Development, joined us on the WTR Small-Cap Spotlight podcast to discuss Veldona, Ainos’ clinical stage low-dose...

Water Tower Research

Ainos, Inc. - Veldona Sjogren's Study Start to Quickly Follow Oral Warts

Taiwan Veldona human study to start in Sjogren’s. Ainos will initiate a Veldona clinical study in Taiwan for primary Sjogren’s syndrome in December...

Water Tower Research

Ainos, Inc. - Veldona Oral Warts Trial to Start in Taiwan Before Year-End

Veldona study design under review by TFDA. Ainos plans to initiate a Veldona clinical study in Taiwan for oral warts in HIV+ patients on...

Water Tower Research

Ainos, Inc. - Adding Coronavirus Treatment and Prevention to Veldona Patent Portfolio

Veldona patent granted in Taiwan for treatment and prevention of coronavirus infection, securing 20 years of patent protection.

Water Tower Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)